MedTrace Logo

AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer

NCT03371485 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-08-09

Study results available
· View outcomes & findings →

Summary

This clinical study is looking at a vaccine called AST-VAC2 in adult patients with advanced non-small cell lung cancer (NSCLC). The main aim of the study: If the dose can be given safely to patients, learn more about the potential side effects of the vaccine and how they can be managed and also what happens to AST-VAC2 inside the body.

Conditions

Interventions

BIOLOGICAL

AST-VAC2

Allogeneic dendritic cell vaccine.

Sponsors & Collaborators

Principal Investigators

  • Gary Middleton, Prof · The Queen Elizabeth Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-29
Primary Completion
2022-08-08
Completion
2022-08-08

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03371485 on ClinicalTrials.gov